Dylann Bailey

Managing Editor for the Journal of Clinical and Aesthetic Oncology

[Targeted Oncology @TargetedOnc]

As September is #ThyroidCancerAwarenessMonth, it is important to highlight how care for thyroid cancer has improved to make most forms of this disease more manageable. #thycsm @AHNtoday @DrWarrenSwegal

https://t.co/2h3UtHtuZJ

[Targeted Oncology @TargetedOnc]

QUIZ: According to the phase 2 KEYNOTE-199 study, what have been the objective response rates for patients with metastatic castration resistant prostate cancer for ICI treatments with tumors without PD-L1 expression and for those with PD-L1–expressing tumors?

[Targeted Oncology @TargetedOnc]

How would you handle this case?

[Targeted Oncology @TargetedOnc]

What is the preferred frontline treatment?

[Targeted Oncology @TargetedOnc]

In interviews for #CancerImmunotherapyMonth, @PatelOncology from @UCSD and @JulieBrahmer from @HopkinsThoracic delve into the advancements of immunotherapy as cancer treatment.
https://t.co/sqYPB1h8Pi

[Sandip Patel MD FASCO @PatelOncology]

Experts Explore Landscape Advancements for Cancer Immunotherapy Month - nice discussion on cancer IO with ⁦@JulieBrahmer⁩ https://t.co/N5nds2gY0j

[Targeted Oncology @TargetedOnc]

Bintrafusp alfa monotherapy demonstrated efficacy, durability, and a manageable safety profile in patients with locally advanced or metastatic biliary tract cancer.
https://t.co/qoeadheYUT

[Targeted Oncology @TargetedOnc]

For #WorldCancerDay, @DrPatton_OneOnc, CEO of @OneOncology, discussed the impact of #COVID19 on cancer treatment and testing in an interview with @TargetedOnc.

https://t.co/cukj1goZu9

[Targeted Oncology @TargetedOnc]

"This is the case of a 73-year-old man with mantle cell lymphoma. He was diagnosed in 2016, and at the time he was treated with a regimen called R-DHAP: rituximab, dexamethasone, cytarabine, and cisplatin." #lymsm
https://t.co/A4dHdyhWzG

[Targeted Oncology @TargetedOnc]

Patients with HR-positive and HER2-negative, aromatase inhibitor resistant metastatic breast cancer experienced improvement in progression-free survival on treatment with chemotherapy over palbociclib with endocrine therapy.
https://t.co/8Pj3XpLike #BCsm

[Targeted Oncology @TargetedOnc]

What would be the next best line of therapy for this patient with #ColorectalCancer once she progresses? Use our tweet chat hashtag #TargetedChat to share your thoughts, & tune in for the discussion with @marklewismd on Wednesday Jan 20 6:00pm EST

[Targeted Oncology @TargetedOnc]

"It’s the medical breakthrough of our lifetime," wrote Mike Hennessy Sr. of @MJHLifeSciences.
https://t.co/pxP2cujfpU #COVID19

[Targeted Oncology @TargetedOnc]

How likely are you to use tafasitamab and lenalidomide as second-line therapy for your patients with R-CHOP-refractory #DLBCL who are transplant ineligible? #LYMsm

[Targeted Oncology @TargetedOnc]

Adjuvant atezolizumab in patients with high-risk muscle-invasive urothelial cancer with detectable circulating tumor DNA demonstrated more benefit compared with those with MIUC and undetectable ctDNA.
https://t.co/gieJUMFsOe #bladdercancer

[Targeted Oncology @TargetedOnc]

ASH POLL: In what area do you think the most important data came from at the 2020 @ASH_hematology Annual Meeting?
Share in the comments what your top #ASH20 abstracts were. #Hematology

[Targeted Oncology @TargetedOnc]

During #LungCancerAwarenessMonth, take a look back at the first episode of the #TargetedTalks podcast on #LungCancer with Dr. Simon of @MDAndersonNews and Dr. Williams @jasonwilliamsmd of @WilliamsCancer. Check out the full episode to hear more: https://t.co/l9DXncG8Y3

[Targeted Oncology @TargetedOnc]

After 2 years of follow-up, the primary efficacy analysis showed that 40% of patient achieved complete remission with the combination of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic #leukemia.
https://t.co/0uigf36nDg #leusm

[Sara Tolaney @stolaney1]

The FDA has granted accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-approved test.

[Targeted Oncology @TargetedOnc]

What percentage of your follow-up visits for patients with #LungCancer have been converted to #Telemedicine?

[Targeted Oncology @TargetedOnc]

Dr. Spira discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.
https://t.co/J8MVfDnWyF #lungcancer #lcsm